Avalyn Pharma (NASDAQ:AVLN) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Avalyn Pharma (NASDAQ:AVLN) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Several other brokerages have also recently issued reports on AVLN. Zacks Research upgraded shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Jefferies Financial Group started coverage on Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $52.00 price target for the company. Weiss Ratings started coverage on Avalyn Pharma in a research note on Thursday, August 13th. They set a “sell (d+)” rating on the stock. Guggenheim started coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $80.00 price objective on the stock. Finally, Evercore started coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Avalyn Pharma Stock Performance

Shares of AVLN opened at $33.57 on Friday. The company has a market capitalization of $1.49 billion and a PE ratio of -1.47. The stock has a fifty day simple moving average of $32.79. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. Avalyn Pharma has a fifty-two week low of $24.15 and a fifty-two week high of $40.17.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.05. As a group, research analysts forecast that Avalyn Pharma will post -3.81 earnings per share for the current year.

Institutional Investors Weigh In On Avalyn Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new position in shares of Avalyn Pharma during the 2nd quarter worth about $1,321,000. Montanova Capital LLC purchased a new stake in Avalyn Pharma in the 2nd quarter worth about $82,402,000. Braidwell LP purchased a new stake in Avalyn Pharma in the 2nd quarter worth about $26,382,000. Finally, California State Teachers Retirement System bought a new stake in Avalyn Pharma in the second quarter worth about $236,000.

Avalyn Pharma Company Profile

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.